Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®
June 14, 2022
- reSET-O® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of opioid use disorder (OUD)
- Results support the real-world value of reSET-O, demonstrating durable treatment outcomes and reductions in healthcare resource utilization
12-month analysis builds on prior publications of population-level improvements in health care resource utilization for reSET-O at 6 and 9 months, as data demonstrated >
$3,800per patient cost savings for the Medicaid population1
Results from a 12-month real-world data study of reSET-O showed a reduction in healthcare utilization, particularly inpatient (IP) stays (which also include ICU stays and readmissions) and emergency department (ED) visits, contributing to a net cost reduction of
This health economic study was accepted for publication and made available via pre-print by the international peer-reviewed journal Advances in Therapy.1
“The data show our health economic outcomes for reSET-O now go out to 12 months, demonstrating durability of the clinical effect for opioid use disorder patients, which is an often difficult to treat patient group as shown in part by the record number of overdose deaths over the last year,” said
The study used claims data to evaluate 901 adult patients
- IP stays (28% reduction; IRR: 0.72; 95% CI: 0.55-0.96; P=0.026) which included a 30% reduction in ICU stays and a 56% reduction in readmissions).
- ED visits (7% reduction; IRR: 0.93; 95% CI: 0.79-1.09; P=0.386).
Per-patient costs across all-payer mix by an estimated
$2,791and per-patient costs for the Medicaid population, specifically by an estimated $3,832reduction.1
Results also showed that among those patients on buprenorphine therapy, adherence significantly increased among those treated with reSET-O vs controls, based on a linear model of the medication possession ratio, despite both groups having similar buprenorphine adherence at baseline.1 Additionally, this study adds to a larger body of evidence for reSET-O that now spans 6, 9 and 12 months both pre-post and vs. controls.
The full paper is available online by clicking here.
reSET-O has been evaluated in randomized controlled trials, in real-world clinical, and real-world health economic studies.1-13
reSET-O Important Safety Information
Indications for Use
reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older
Important Safety Information:
Warnings: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and
reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.
Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.
The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.
This press release contains forward-looking statements within the meaning of the federal securities laws that are subject to risks and uncertainties and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally relate to future events involving, or future performance of, Pear. For example, statements about the real-world value of reSET-O or statements concerning reSET-O’s durable treatment effect and/or associated reductions in healthcare resource utilization are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “can” or variations of them or similar terminology.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Pear and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) delay or reluctance by patients and/or providers to adopt, request or use Pear’s products, (ii) the possibility that Pear may be adversely affected by other economic, business, regulatory, and/or competitive factors; (iii) the evolution of the markets in which Pear competes; (iv) the impact of the COVID-19 pandemic on Pear’s business; (v) changes in applicable laws or regulations; and (vi) other risks and uncertainties set forth in Pear’s filings with the
Readers are cautioned not to put undue reliance on forward-looking statements, and Pear assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Fulton F. Velez, Kathryn Anastassopoulos, Sam Colman, Neel Shah, Laura Kauffman, Sean M. Murphy, Charles Ruetsch& Yuri Maricich(2022). Reduced healthcare resource utilization in patients with opioid use disorder in the 12 months after initiation of a prescription digital therapeutic. Advances in Therapy. 2022; https://doi.org/10.6084/m9.figshare.20013323.v1.
Fulton F. Velez, Charles Ruetsch& Yuri Maricich(2021). Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1939687.
Fulton F. Velez, Sam Colman, Laura Kauffman, Charles Ruetsch& Kathryn Anastassopoulos(2020). Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1840357.
- Christensen DR, Landes RD, Jackson L, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964-972. doi:10.1037/a0037496.
Yuri A. Maricich, MD, Xiaorui Xiong, PhD, Robert Gerwien, PhD, Alice Kuo, BA Fulton Velez, MD MBA, Bruce Imbert, MD PhD, Keely Boyer, MBA, Hilary F. Luderer, PhD, Stephen Braun, BA, Karren Williams, PhD (2020): Real-World evidence for a prescription digital therapeutic to treat Opioid Use Disorder, Journal of Current Medical Research and Opinion, DOI:10.1080/03007995.2020.1846023.
Fulton F. Velez, Sam Colman, Laura Kauffman, Charles Ruetsch& Kathryn Anastassopoulos(2020): Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1840357.
Weijia Wang, Nicole Gellings Lowe, Ali Jalali& Sean M. Murphy(2021) Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder, Journal of Medical Economics, 24:1, 61-68, DOI: 1080/13696998.2020.1858581.
Yuri A. Maricich, Warren K. Bickel, Lisa A. Marsch, Kirstin Gatchalian, Jeffrey Botbyl& Hilary F. Luderer(2020) Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder, Current Medical Researchand Opinion, DOI: 1080/03007995.2020.1846022.
Fulton F. Velez, Hilary F. Luderer, Robert Gerwien, Benjamin Parcher, Dylan Mezzio& Daniel C. Malone(2021) Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder, Postgraduate Medicine, DOI: 1080/00325481.2021.1884471.
Fulton F. Velez, Charles Ruetsch& Yuri Maricich(2021) Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 1080/14737167.2021.193968.
Fulton F. Velez& Daniel C. Malone(2021) Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder, Journal of Market Access & Health Policy, 9:1, DOI: 1080/20016689.2021.1966187.
Yuri A. Maricich, Robert Gerwien, Alice Kuo, Daniel C. Malone& Fulton F. Velez(2021) Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder, Hospital Practice, DOI: 1080/21548331.2021.1974243.
Velez FF, Colman S, Kauffman L, Ruetsch C, Anastassopoulos K, Maricich YA. Comparison of Healthcare Resource Utilization Between Patients
WhoEngaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder. Clinicoecon Outcomes Res. 2021;13:909-916
Media and Investors:
Senior Director, Corporate Communications